HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia.

AbstractPURPOSE:
To assess the safety of long-term cevimeline treatment of radiation-induced xerostomia in patients with head-and-neck cancer; and to assess the efficacy of cevimeline in these patients.
METHODS AND MATERIALS:
A total of 255 adults with head-and-neck cancer who had received more than 40 Gy of radiation 4 months or more before entry and had clinically significant salivary gland dysfunction received cevimeline hydrochloride 45 mg t.i.d. orally for 52 weeks. Adverse events (AEs), their severity, and their relationship to the study medication were assessed by each investigator. The efficacy assessment was based on subjects' global evaluation of oral dryness on a scale of 0 (none) to 3 (severe).
RESULTS:
Overall, 175 subjects (68.6%) experienced expected treatment-related AEs, most mild to moderate. The most frequent was increased sweating (47.5%), followed by dyspepsia (9.4%), nausea (8.2%), and diarrhea (6.3%). Fifteen subjects (5.9%) experienced Grade 3 treatment-related AEs, of which the most frequent was increased sweating. Eighteen subjects (7.1%) reported at least one serious AE, and 45 subjects (17.6%) discontinued study medication because of an AE. The global efficacy evaluation at the last study visit showed that cevimeline improved dry mouth in most subjects (59.2%). Significant improvement was seen at each study visit in the mean change from baseline of the numeric global evaluation score (p < 0.0001).
CONCLUSIONS:
Cevimeline 45 mg t.i.d. was generally well tolerated over a period of 52 weeks in subjects with xerostomia secondary to radiotherapy for cancer in the head-and-neck region.
AuthorsMark S Chambers, Christopher Uwe Jones, Merrill A Biel, Randal S Weber, Kenneth M Hodge, Y Chen, John M Holland, Jonathan A Ship, Robert Vitti, Ingrid Armstrong, Adam S Garden, Robert Haddad
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 69 Issue 5 Pg. 1369-76 (Dec 01 2007) ISSN: 0360-3016 [Print] United States
PMID17855005 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Muscarinic Agonists
  • Quinuclidines
  • Thiophenes
  • cevimeline
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Diarrhea (chemically induced)
  • Dyspepsia (chemically induced)
  • Female
  • Head and Neck Neoplasms (radiotherapy)
  • Humans
  • Male
  • Middle Aged
  • Muscarinic Agonists (administration & dosage, adverse effects)
  • Nausea (chemically induced)
  • Quinuclidines (administration & dosage, adverse effects)
  • Radiotherapy Dosage
  • Sweat (drug effects)
  • Thiophenes (administration & dosage, adverse effects)
  • Xerostomia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: